Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11290
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNicholaou, Theoen
dc.contributor.authorChen, Weisanen
dc.contributor.authorDavis, Ian Den
dc.contributor.authorJackson, Heather Men
dc.contributor.authorDimopoulos, Nektariaen
dc.contributor.authorBarrow, Catherineen
dc.contributor.authorBrowning, Judyen
dc.contributor.authorMacgregor, Duncanen
dc.contributor.authorWilliams, Daviden
dc.contributor.authorHopkins, Wendieen
dc.contributor.authorMaraskovsky, Eugeneen
dc.contributor.authorVenhaus, Ralphen
dc.contributor.authorPan, Lindaen
dc.contributor.authorHoffman, Eric Wen
dc.contributor.authorOld, Lloyd Jen
dc.contributor.authorCebon, Jonathan Sen
dc.date.accessioned2015-05-16T00:52:46Z
dc.date.available2015-05-16T00:52:46Z
dc.date.issued2011-06-23en
dc.identifier.citationCancer Immunology, Immunotherapy : Cii 2011; 60(11): 1625-37en
dc.identifier.govdoc21698545en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11290en
dc.description.abstractNY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial.Immunity was measured in 28 patients with resected NY-ESO-1-expressing tumours (melanoma 25, breast 3) 252-1,155 days (median = 681) after vaccination. In the earlier vaccination, trial patients received NY-ESO-1 with ISCOMATRIX™ adjuvant at three protein doses 10 μg, 30 μg or 100 μg (n = 14); 100 μg NY-ESO-1 protein (n = 8) or placebo (n = 6), together with 1 μg of intradermal (ID) NY-ESO-1 protein twice for DTH skin testing. Immune responses assessed in the current study included antibody titres, circulating NY-ESO-1-specific T cells and DTH reactivity 2 days after DTH skin testing with NY-ESO-1 protein (1 μg) or peptides (10 μg). Relapse-free survival was determined for 42 melanoma patients. On relapse NY-ESO-1 and HLA, class I was assessed by immunohistochemistry in 17.Persisting anti-NY-ESO-1 immunity was detected in 10/14 recipients who had previously received vaccine with ISCOMATRIX™ adjuvant. In contrast, immunity only persisted in 3/14 who received 100 μg un-adjuvanted NY-ESO-1 protein (3/8) or 2 μg DTH protein (0/6) P = 0.02. Hence, persisting NY-ESO-1 immunity was associated with prior adjuvant. Tumour NY-ESO-1 or HLA class I was downregulated in participants who relapsed suggesting immunoediting had occurred.Immunoediting suggests that a signal of anti-tumour activity was observed in high-risk resected melanoma patients vaccinated with NY-ESO-1/ISCOMATRIX™. This was associated with measurable persisting immunity in the majority of vaccinated subjects tested. A prospective randomised trial has been undertaken to confirm these results.en
dc.language.isoenen
dc.subject.otherAdjuvants, Immunologic.administration & dosageen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAmino Acid Sequenceen
dc.subject.otherAntigens, Neoplasm.administration & dosage.biosynthesis.immunologyen
dc.subject.otherBreast Neoplasms.immunology.therapyen
dc.subject.otherCancer Vaccines.administration & dosage.immunologyen
dc.subject.otherCholesterol.administration & dosage.immunologyen
dc.subject.otherDisease-Free Survivalen
dc.subject.otherDown-Regulationen
dc.subject.otherDrug Combinationsen
dc.subject.otherDrug Hypersensitivity.etiology.immunologyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherImmunohistochemistryen
dc.subject.otherMaleen
dc.subject.otherMelanoma.immunology.therapyen
dc.subject.otherMembrane Proteins.administration & dosage.biosynthesis.immunologyen
dc.subject.otherMiddle Ageden
dc.subject.otherMolecular Sequence Dataen
dc.subject.otherPhospholipids.administration & dosage.immunologyen
dc.subject.otherProspective Studiesen
dc.subject.otherSaponins.administration & dosage.immunologyen
dc.subject.otherSkin.immunologyen
dc.titleImmunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer immunology, immunotherapy : CIIen
dc.identifier.affiliationLudwig Institute for Cancer Research, Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1007/s00262-011-1041-3en
dc.description.pages1625-37en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/21698545en
dc.type.austinJournal Articleen
local.name.researcherCebon, Jonathan S
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Files in This Item:
File SizeFormat 
21698545.pdf66.11 kBAdobe PDFView/Open
Show simple item record

Page view(s)

16
checked on Mar 27, 2024

Download(s)

68
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.